Read the study in full: doi.org/10.1186/s128...

@hepbvoicesau.bsky.social @hepatitisaustralia.bsky.social @genevieveemart1.bsky.social @thedohertyinst.bsky.social

@thedohertyinst.bsky.social @hepatitisaustralia.bsky.social @steventong.bsky.social @gurujosh.bsky.social

The Hep B PAST program is delivering real change 🙌 This latest study is part of this innovative program by @menziesresearch.bsky.social improving hepatitis B outcomes. Proud to have been able to work with this team.

www.thelancet.com/journals/lan...

This large cohort study estimates key clinical parameters for sub-genotype C4 hepatitis B virus (uniquely found in Northern Australia), and explores the potential impact of expanded @who.int treatment guidelines in this context.

particularly acute kidney injury, bone marrow suppression, and severe cutaneous reactions, affecting over 50% of patients exposed. Notably, 44% required cessation or dose reduction due to toxicity
www.sciencedirect.com/science/arti...

www.sciencedirect.com/science/arti...
@idsainfo.bsky.social

For a case-based discussion about melioidosis 🧫 listen to our @febrilepodcast.bsky.social episode “Of Microbes and Mud” from earlier this year. febrilepodcast.com/febrile-94-o...

Trimethoprim / sulfamethoxazole is a key antibiotic 💊 used in the treatment of melioidosis. Over a 5-year period we show that >50% of individuals treated for melioidosis with this drug have an adverse reaction. #ISID #IJID doi.org/10.1016/j.ij...

We systematically looked at cases of melioidosis with and without respiratory viral co-infection 😷 in @ofidjournal.bsky.social and found no evidence of a clinical difference between these groups. academic.oup.com/ofid/advance...